Published in Contemp Oncol (Pozn) on January 25, 2014
Marine compounds inhibit growth of multiple myeloma in vitro and in vivo. Oncotarget (2015) 0.77
Consolidation in multiple myeloma - current status and perspectives. Contemp Oncol (Pozn) (2014) 0.75
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood (2012) 5.11
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res (2007) 3.85
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol (2004) 3.37
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood (2012) 2.41
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol (2012) 1.94
Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood (2012) 1.91
Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia (2013) 1.84
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia (2010) 1.77
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol (2008) 1.71
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia (2013) 1.56
Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma (2012) 1.47
Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. Eur J Haematol (2005) 0.88
Acute lung toxicity related to pomalidomide. Chest (2011) 0.84
Proteasome inhibitor therapy for Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk (2013) 0.80
A third-generation IMiD for MM. Blood (2011) 0.79
Idiopathic, asymptomatic, and durable blood hypereosinophilia-still many unknowns. J Allergy Clin Immunol (2014) 1.08
Advances in the diagnosis and treatment of eosinophilia. Curr Opin Hematol (2014) 0.85
Occurrence of secondary malignancies in chronic myeloid leukemia during therapy with imatinib mesylate-single institution experience. Mediterr J Hematol Infect Dis (2015) 0.83
Autologous Hematopoietic Stem Cell Transplantation for High-risk Acute Lymphoblastic Leukemia: non-Randomized Study with a maximum Follow-up of more than 22 Years. Mediterr J Hematol Infect Dis (2014) 0.79
Autologous stem cell transplantation for mantle cell lymphoma - single centre experience. Contemp Oncol (Pozn) (2013) 0.78
Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients. Biol Blood Marrow Transplant (2015) 0.76
Cytotoxic activity of valproic acid on primary chronic lymphocytic leukemia cells. Adv Clin Exp Med (2015) 0.75
Minimally invasive, endovenous laser treatment of varicose veins in patients with von Willebrand disease. Ann Agric Environ Med (2013) 0.75
Is it time for erythropoietin use in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients? Chin Clin Oncol (2012) 0.75
Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study. Clin Lymphoma Myeloma Leuk (2017) 0.75